We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Solid Biosciences Inc. (NASDAQ:SLDB) stands against other stocks with at least $20 million in insider spending recently.
As the stock market navigates a complex environment shaped by recent trade policies, mixed economic signals, and new geopolitical circumstances, investors must remain vigilant. While many experts raise concerns about potential increased volatility under Trump, some analysts believe he is the most pro-stock market president in U.S. history.
On Monday, one day before Trump’s 25% tariffs on goods imported from Canada and Mexico into the U.S. were set to take effect, markets declined. The broader market fell 1.8%, marking its biggest one-day drop of the year, while tech stocks saw a 2.6% decline.
“No room left for Mexico or for Canada,” Trump said at the White House on Monday. “The tariffs, you know, they’re all set. They go into effect tomorrow.”
With no certainty about how long these fluctuations will continue, investors seem to be growing more cautious. While it’s difficult to predict what will happen next, some experts believe that the U.S. Federal Reserve might cut interest rates.
Equity strategists in a Reuters poll project that the broader market will finish the year 9% higher than its current level. Morgan Stanley’s Andrew Slimmon suggests that the adoption of AI could lead to a productivity boom, similar to what happened with the Internet in the late 1990s.
Amid market fluctuations and uncertainty, insider trading also comes into focus. Executives and insiders, with their valuable insights into company strategy, plans, and future moves, may have trades worth analyzing. For example, when a CEO or CFO invests their own money in company shares, it can signal strong confidence in the company’s potential.
However, it is important to highlight that both insider buying and selling can be driven by various motives; therefore, these actions should be considered only within a broader context of the company’s fundamentals, industry trends, and market conditions. This is why due diligence is crucial before making any investment. Insider trading activity, along with other relevant factors, can offer valuable insights into a company’s capabilities, helping investors make more informed decisions.
Today, we will focus on stocks that have seen at least $20 million in insider spending recently. For this purpose, we used Insider Monkey’s insider trading stock screener, focusing on stocks where at least one insider purchase over the last three months was valued at $20 million or more. Although the total value of insider purchases during this period may be higher, only those worth $20 million or more were considered in this search. Since there were more than 10 stocks meeting this criterion, we selected the 10 stocks with insider purchases ranging from $20 million to $35 million, choosing those with the highest amounts within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual purchase, the number of insider purchases between $20 million and $35 million over the last three months and the company’s current market capitalization.
Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently?
A specialist in a lab coat and goggles looking up at a gene sample, testing for the latest therapies.
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $426.21 million
Solid Biosciences Inc. (NASDAQ:SLDB) is a life science company, engaged in the development of therapies for neuromuscular and cardiac diseases in the U.S. The Charleston, Massachusetts-based company has several leading product candidates in the pipeline. One of them is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; another one is SGT-501, designed to help with Catecholaminergic polymorphic ventricular tachycardia.
On February 19, one insider purchased $20.15 million worth of Solid Biosciences Inc. (NASDAQ:SLDB) shares at $4.03 per share. This acquisition was part of the company’s underwritten offering of 35.74 million shares of its common stock. The company said it expected $200 million in the aggregate gross proceeds of the offering. Currently, the stock is trading at $5.12, having gained 28% year-to-date.
In February, Solid Biosciences also announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003. Interim 90-day biopsy data reported in the first three participants showed an average microdystrophin expression of 110%, as measured by western blot, and improvements in multiple biomarkers that are indicators of muscle health and resilience.
“Three different measurement methodologies showed what we believe to be potential best-in-class expression of our differentiated microdystrophin transgene,” commented Bo Cumbo, president and CEO of Solid Biosciences. Cumbo also added in mid-2025 the company plans to talk with the FDA about the potential for an accelerated approval regulatory pathway for SGT-003.
Nine Wall Street analysts have given an average “Strong Buy” for Solid Biosciences, writes TipRanks. Their average price target is $16.86, indicating a 229.3% increase from the previous price.
Overall, SLDB ranks 9th on our list of stocks with at least $20 million in insider spending recently. While we acknowledge the potential of SLDB as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLDB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
